Annexon Inc. - ANNX EV/EBITDA Multiple
Annexon, Inc. (ANNX) logistics are based on strict adherence to temperature control during transport, which increases costs but guarantees medication quality. The company's human capital is strengthened by the loyalty of immunologists and the recruitment of clinical trial experts through stock option programs. The market dynamics reflected in the quotes show an EV/EBITDA of 0.00, underscoring the value of strategic partnerships with biopharmaceutical behemoths to create innovative therapies.
annexonbio.com - analytical breakdowns and key metrics (ANNX)
- market price and analyst price targets:
- issuer market value details:
- issuer book value statistics:
- debt and liquidity data:
- net income and valuation multiples indicators:
ANNX - Net Income|Future Profit Annexon, Inc.|ANNX - Business Payback Period|Forward P/E Multiple Annexon, Inc.|ANNX - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Annexon Biosciences Inc.|ANNX - Operating profit before amortization|Earnings per share for the last twelve months Annexon|ANNX - Earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months annexonbio.com|ANNX - Earnings per share growth this year|Net earnings per share growth forecast for next year Annexon, Inc.
Summary company analysis:Annexon Inc. ANNX
The ratio compares the total value of assets and debt with operating profit, excluding the impact of tax regimes and depreciation. This metric determines the real value of the business, allowing investors to identify undervalued capacities relative to cash flow. For Annexon, Inc. (ANNX), pipeline diversification in neurology mitigates risks, stabilizing the fundamental basis for calculations. By analyzing the EV/EBITDA dynamics of the business, one can assess the resilience of the company's capitalization to potential clinical failures.
Analysis of competing companies
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Biogen Corp BIIB|NBIX: Enterprise Value to Operating Income Before Depreciation|Regencell Bioscience - EV/EBITDA Multiple|Company Value to EBITDA axsome.com|ACAD (ACADIA Pharmaceuticals Inc.) - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation XENE|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Viking Pharma|Company Value to EBITDA Supernus Corp SUPN|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Catalyst Pharmaceuticals (CPRX)|denalitherapeutics.com - Enterprise Value to Operating Income Before Depreciation|Harmony Biosciences Holdings, Inc. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation BHVN|Amylyx - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Trevi Corp TRVI|Praxis Precision Medicines (PRAX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation AVXL|CBLL (CeriBell) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Prothena Corporation PLC (PRTA)|Enterprise Value to EBITDA Ratio ALEC (Alector, Inc.)|Total Company Value to Operating Income Before Depreciation Ratio omeros.com|EV/EBITDA Multiple NGNE (Neurogene Inc.)|EV/EBITDA Multiple acimmune.com ACIU|VYGR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|NMRA (Neumora) - Enterprise Value to Operating Income Before Depreciation|Scilex Holding Co. (SCLX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation TVGN|Enterprise Value to EBITDA Ratio ACOG|Enterprise Value to Operating Income Before Depreciation CGTX (cogrx.com)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Inhibikase Therapeutics, Inc. (IKT)|Cassava Sciences Inc - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple ASRT (Assertio)|Coya Therapeutics Inc (COYA) - Company Value to EBITDA|VTGN: Enterprise Value to EBITDA Ratio|OVID - EV/EBITDA Multiple|Acumen Pharmaceuticals, Inc. (ABOS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CervoMed, Inc. - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alterity Therapeutics Ltd.|Company Value to EBITDA Clene Nanomedicine CLNN|EV/EBITDA Multiple PEPG|EV/EBITDA Multiple jupiterneurosciences.com (JUNS)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Relmada Therapeutics, Inc. RLMD|ANVS: Enterprise Value to Operating Income Before Depreciation|GRCE - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|AIFF (Firefly Neuro) - Enterprise Value to Operating Income Before Depreciation|KLTO: EV/EBITDA Multiple|Company Value to EBITDA NeuroSense Therapeutics Ltd. (NRSN)|Enterprise Value to EBITDA Ratio RVPH|Enterprise Value to Operating Income Before Depreciation MTVA (MetaVia, Inc.)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NeurAxis, Inc (NRXS)|HSDT - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Passage Bio PASG|NEUP: Enterprise Value to Operating Income Before Depreciation|NERV: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation ATHA (Athira Pharma Inc)|ADXN: EV/EBITDA Multiple|ALZN - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cyclerion Therapeutics Inc.|Enterprise Value to Operating Income Before Depreciation PTIX (Protagenic)|EV/EBITDA Multiple KTTA|Enterprise Value to EBITDA Ratio cortigent.com CRGT|Avenue Therapeutics, Inc - Enterprise Value to EBITDA Ratio|Total Company Value to Operating Income Before Depreciation Ratio BrainStorm Cell Therapeutics Inc. (BCLI)|Cara Therapeutics, Inc. - EV/EBITDA Multiple|CHRO - EV/EBITDA Multiple|eliemtx.com (ELYM) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation ITCI|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Longboard Pharma|Enterprise Value to Operating Income Before Depreciation MRNS (Marinus Pharma)|Enterprise Value to EBITDA Ratio NKGN (NKGen Biotech, Inc.)|neurobopharma.com - Enterprise Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Sage Therapeutics SAGE|SNPX: Enterprise Value to Operating Income Before Depreciation|Trevena, Inc - EV/EBITDA Multiple|Company Value to EBITDA Vigil Neuroscience|WENA (Anew Medical, Inc.) - Enterprise Value to EBITDA Ratio|cerevel.com (CERE) - EV/EBITDA Multiple
